Helicobacter pylori eradication therapy: Indications, efficacy and safety

Expert Opinion on Drug Safety

Volumn 7, Issue 3, 2008, Pages 271-281

  Kwok, Avelyn ^a   Lam, Thao ^a   Katelaris, Peter ^a   Leong, Rupert W L ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Allergy; Antibiotic; Clarithromycin; Consensus; Eradication; Helicobacter pylori; Penicillin; Rescue therapy; Resistance; Salvage therapy; Triple therapy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISMUTH SALICYLATE; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; NITROIMIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN G; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; STOMACH SECRETION INHIBITOR; TETRACYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT; NITROIMIDAZOLE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; FECES; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMOLYTIC ANEMIA; HUMAN; LEUKOPENIA; LIVER DISEASE; MALAISE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; NONHUMAN; PENICILLIN ALLERGY; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; STOMACH CANCER; TASTE DISORDER; THROMBOCYTOPENIA; TONGUE; TOOTH DISCOLORATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; DRUG ADMINISTRATION; DRUG COMBINATION; DUODENUM ULCER; MICROBIOLOGY; STOMACH TUMOR; STOMACH ULCER;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DUODENAL ULCER; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; NITROIMIDAZOLES; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS; STOMACH ULCER;

EID: 44949247457     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.3.271     Document Type: Review

References (87)

1. Hunt RH, Xiao SD, Megraud F, et al. WGO practice guideline: Helicobacter pylori in developing countries. Updated 5 February 2007. Available from: http://www.worldgastroenterology.org/ helicobacter-pylori-in-developing-countries.html [last accessed 1 April 2008]
2. Graham DY. Can therapy ever be denied for Heicobacter pylori infection? Gastroenterology 1997;113(Suppl 6):S113-7
3. Rautelin H, Kosunen TU. Helicobacter pylori infection in Finland. Ann Med 2004;36:82-8
4. Windsor HM, Abioye-Kuteyi EA, Leber JM, et al. Prevalence of Helicobacter pylori in Indigenous Western Australians: comparison between urban and remote rural populations. Med J Aust 2005;182:210-3
5. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol 1996;31(Suppl 215):38-47
6. Malfertheiner P, Megraud F, O'Morain C, et al. The European Helicobacter Study Group (EHSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81
7. Janssen MJR, Van Oijen A, Verbeek ALM, et al. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Ailment Phamacol Ther 2001;15:613-24
8. Katelaris PH, Forbes GM, Talley NJ, et al. A randomised comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE study. Gastroenterol 2002;123:1763-9
9. Gomollon F, Ducons JA, Ferrero M, et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999;4:222-5
10. Ford AC, Delaney BC, Forman D, et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55
11. Sung JJ, Leung WK, Suen R, et al. One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding. Dig Dis Sci 1997;42:2524-8
12. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22
13. Leong RW, Chan FK, Sung JJ. Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Approaching the end of the controversy in the new millennium, or room for more debate? J Gastroenterol 2001;36:731-9
14. Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-8
15. Raghunath AS, Hungin AP, Wooff D, et al. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004;20:733-44
16. Chan FKL, Chung SCS, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73
17. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterol 2005;128:1579-605
18. Montalban C, Norman F. Treatment of gastric mucosa associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond. Expert Rev Anticancer Ther 2006;6:361-71
19. Roher HD, Vereet PR, Wormer O, et al. Helicobacter pylori in the upper gastrointestinal tract: medical or surgical treatment of gastric lymphoma? Langenbecks Arch Surg 2000;385:97-105
20. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case-control studies nested within prospective cohorts. Gut 2001;49:347-53
21. Zhou L, Sung GJJ, Lin S, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J 2003;116:11-4
22. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94
23. Nardone G, Staibano S, Rocco A, et al. Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Gut 1999;44:789-99
24. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001
25. Leung WK, Ng EK, Chan WY, et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14:2982-6
26. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;2:CD002096
27. McNamara D, Buckley M, Gilvarry J, et al. Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia? A 5-year follow-up study. Helicobacter 2002;7:317-21
28. Chey WD, Wong BCY; Practice Parameters Committee of the American College Of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25
29. Ford A, McNauty C, Delaney B, et al. Helicobacter pylori infection. BMJ Clin Evid 2007;6:406-19
30. Kaffes A, Cullen J, Mitchell H, et al. Effect of Helicobacter pylori infection and low-dose aspirin use on iron stores in the elderly. J Gastroenterol Hepatol 2003;18:1024-8
31. Gasbarrini A, Franceschi F, Tarraglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998;352:878
32. Leong RW, Sung JJ. Helicobacter species and hepatobiliary diseases. Aliment Pharmacol Ther 2002;16:1037-45
33. Manolakis A, Kapsoritakis AN, Potamianos SP. A review of the postulated mechanisms concerning the association of Helicobacter pylori with ischemic heart disease. Helicobacter 2007;12:287-97
34. Leung WK, Hung LC, Kwok CK, et al. Follow-up of serial urea breath test results in patients after consumption of antibiotics for non-gastric infections. World J Gastroenterol 2002;8:703-6
35. Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;21:91-6
36. Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 2007;12(Suppl 2):50-8
37. Penston JG, Mccoll KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997;43:223-43
38. Gisbert JP, Khorrami S, Carballo F, et al. H. pylori eradication therapy vs antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004;2:CD004062
39. Gisbert JP, Pahares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig Liver Dis 2004;36:253-9
40. Hojo M, Miwa H, Nagahara A, et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700
41. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84
42. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319-28
43. Dore MP, Leandro G, Realdi G, et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000;45:68-76
44. Zullo A, De Francesca V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7
45. Janssen MJ, Laheij RJ, De Boer WA, et al. Meta-analysis: the influence of pretreatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol Ther 2005;21:341-5
46. Graham DY, Hammoud F, El-Zimaity HM, et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:1229-36
47. Fuccio L, Minardi EM, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62
48. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-9
49. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003;17(Suppl B):B36-40
50. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43
51. Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy: results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17:99-109
52. Houben M, Van De Beek D, Hensen E, et al. A systematic review of Helicobacter eradication therapy: the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55
53. Suzuki T, Matsuo K, Sawaki A, et al. Systematic review and meta-analysis: Importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2006;24:273-80
54. Padol S, Yuan Y, Thabane M, et al. The effect of CTP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006;101:1467-75
55. Gisbert JP, Gisbert JL, Marcos S, et al. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 2005;22:1041-6
56. Vakil N, Lanza F, Schwartz H, et al. Seven-day triple therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004;20:99-107
57. Zullo A, Hassan C, Lorenzetti R, et al. Helicobacter pylori eradication: do we have another ace up our sleeve? Dig Liver Dis 2001;33:805-6
58. Nagahara A, Miwa H, Ohkura R, et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001;16:613-8
59. Gisbert JP, Boixeda D, Bermejo F, et al. Retreatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999;11:1049-54
60. Lerang F, Moum B, Haug JB, et al. Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy. Scand J Gastroenterol 1997;32:1209-14
61. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based therapies fail. Aliment Pharmacol Ther 2002;16:1047-57
62. Peitz U, Sulluga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomised study. Aliment Pharmacol Ther 2002;16:315-24
63. Zullo A, Hassan C, Campo SM, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001;15:1193-7
64. Gisbert JP, Gisbert JL, Marcos S, et al. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999;13:1311-6
65. Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006;119:217-24
66. Saad R, Schoenfield P, Kim H, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastro 2006;101:488-96
67. Miyachi H, Miki I, Aoyama N, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006;11:243-9
68. Bogaerts P, Berhin C, Nizet H, et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006;11:441-5
69. Carroir V, Necroux J, Lascols C, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007;29:389-96
70. Akada JK, Shirai M, Fujii K, et al. In-vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob Agents Chemother 1999;43:1072-6
71. Gonzalez Carro P, Pérez Roldan F, De Pedro Esteban A, et al. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol 2007;22:60-3
72. Perri F, Festa V, Clemente R, et al. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-6
73. Bock H, Koop H, Lehn N, et al. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000;31:222-5
74. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007;26:1537-42
75. Perri F, Festa V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62
76. Wong WM, Wong BC, Lu H, et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002;16:793-8
77. Fakheri H, Merat S, Malekzadeh R, et al. Low dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004;19:89-93
78. Zullo A, Hassan C, Lorenzetti R, et al. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003;35:357-61
79. Gomollón F, Sicilia B, Ducóns JA, et al. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000;14:1335-8
80. Leong RW, Lee CC, Ling TK, et al. Evaluation of the string test for the detection of Helicobacter pylori. World J Gastroenterol 2003;9:309-11
81. Gisbert JP, Gisbert JL, Marcoa S, et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006;24:1469-74
82. Gisbert JP, Gisbert JL, Marcos S, et al. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008;27:346-54
83. Croom K, Goa K. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003;63:2769-802
84. Borody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:481-8
85. Canducci AF, Ojetta V, Pola P, et al. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther 2001;15:143
86. Coelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005;21:783-7
87. Graham DY, Osato MS, Hoffman J, et al. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000;14:211-5